GlassScriptPhysician profile
Kathryn A Arrambide
NPI 1518946508
$28,729.29
in general payments reported to CMS, 2019-2025
59 companies · $6,908 in 2025
The $6,908 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2021: $4,120 · 2022: $3,538 · 2023: $7,413 · 2024: $6,533 · 2025: $6,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $5,363 · Travel and Lodging: $1,191 · Education: $422 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,678.00 |
| Food and Beverage | $5,363.15 |
| Travel and Lodging | $1,191.03 |
| Education | $421.97 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,814.91 | 2022-2025 | Imfinzi, Lynparza, Calquence |
| Incyte Corporation | $6,381.17 | 2022-2025 | Jakafi, Monjuvi |
| Glaxosmithkline, LLC. | $2,926.88 | 2021-2024 | Zejula, Jemperli |
| Janssen Scientific Affairs, LLC | $1,237.01 | 2019-2023 | Rybrevant |
| Daiichi Sankyo INC. | $1,206.56 | 2022-2025 | Vanflyta, Enhertu, Injectafer |
| Morphosys, US INC. | $1,140.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $826.91 | 2019-2025 | |
| Beigene USA, INC. | $740.79 | 2023-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $577.05 | 2019-2024 | Opdivo, Opdualag |
| Pfizer INC. | $386.08 | 2022-2025 | |
| Janssen Biotech, INC. | $381.47 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Merck Sharp & Dohme LLC | $278.45 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Genzyme Corporation | $253.34 | 2021-2025 | |
| Astellas Pharma US INC | $236.17 | 2022-2025 | Xtandi, Padcev |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $231.27 | 2024-2025 | |
| Sobi, INC | $210.97 | 2022-2025 | |
| Celgene Corporation | $209.58 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Pharmacosmos Therapeutics INC. | $169.13 | 2024-2025 | Monoferric, Cosela |
| Amgen INC. | $167.38 | 2019-2023 | Kyprolis, Blincyto |
| Dendreon Pharmaceuticals LLC | $164.03 | 2023 | Provenge |
| Lilly USA, LLC | $138.32 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $132.40 | 2019-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $127.60 | 2023-2025 | Libtayo |
| Seagen INC. | $125.37 | 2021-2023 | Padcev |
| Alexion Pharmaceuticals, INC. | $122.08 | 2024-2025 | Ultomiris |
| Adc Therapeutics America, INC. | $105.69 | 2022-2025 | |
| Genentech USA, INC. | $96.51 | 2019-2024 | Tecentriq, Polivy, Columvi |
| Array Biopharma INC | $88.52 | 2025 | Mektovi, Xalkori, Lorbrena |
| Eisai INC. | $84.85 | 2022-2025 | |
| Pharmaessentia USA Corporation | $81.70 | 2023 | Besremi |
| Ipsen Biopharmaceuticals, INC | $65.85 | 2025 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $63.03 | 2022-2023 | Alunbrig |
| Stemline Therapeutics INC. | $60.82 | 2023-2024 | Orserdu |
| Rigel Pharmaceuticals, INC. | $53.46 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Progenics Pharmaceuticals, INC. | $49.25 | 2023 | Pylarify |
| Caris Mpi, INC. | $48.63 | 2025 | Mi Cancer Seek |
| G1 Therapeutics, INC. | $39.76 | 2022-2023 | Cosela |
| Adaptive Biotechnologies Corporation | $39.50 | 2022-2023 | Clonoseq |
| Genmab U.S., INC. | $36.61 | 2023-2025 | Epkinly |
| Mirati Therapeutics, INC. | $33.97 | 2023 | Krazati |
| Blueprint Medicines Corporation | $25.09 | 2025 | Ayvakit |
| Puma Biotechnology, INC. | $23.41 | 2025 | |
| Kyowa Kirin, INC. | $22.00 | 2025 | |
| Recordati_rare_diseases_inc. | $21.84 | 2023 | Sylvant |
| Verity Pharmaceuticals INC. | $21.60 | 2023 | Trelstar |
| Aveo Pharmaceuticals, INC. | $20.81 | 2024 | |
| Myovant Sciences INC. | $20.39 | 2022 | |
| Deciphera Pharmaceuticals INC. | $19.58 | 2022 | |
| Sirtex Medical INC | $19.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.16 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.44 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.10 | 2022 | |
| Tactile Systems Technology INC | $15.92 | 2024 | Entre Plus, Flexitouch Plus |
| Beone Medicines USA, INC. | $15.35 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $15.21 | 2022 | |
| Taiho Oncology, INC. | $14.24 | 2024 | |
| Exelixis INC. | $13.75 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Arrambide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.